Page last updated: 2024-10-21

ibotenic acid and Brain Injuries

ibotenic acid has been researched along with Brain Injuries in 57 studies

Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.

Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.

Research Excerpts

ExcerptRelevanceReference
"We have investigated whether administration of staurosporine, which has been reported to induce differentiation in the human neuroblastoma cell in vitro, attenuates amnesia induced by basal forebrain lesion in rats."7.68Staurosporine, a protein kinase inhibitor, attenuates basal forebrain-lesion-induced amnesia and cholinergic neuronal deficit. ( Fuji, K; Kameyama, T; Nabeshima, T; Nishimura, H; Ogawa, S; Sasaki, Y, 1991)
"Ibotenic acid injected intracerebrally over a broad dose range to 5-day-old mice induces cystic white matter (WM) lesions that mimic periventricular leukomalacia (PVL) of preterm infants."3.74Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs. ( Carmeliet, P; Hennebert, O; Laudenbach, V; Legros, H; Leroux, P; Marret, S, 2007)
"We have investigated whether administration of staurosporine, which has been reported to induce differentiation in the human neuroblastoma cell in vitro, attenuates amnesia induced by basal forebrain lesion in rats."3.68Staurosporine, a protein kinase inhibitor, attenuates basal forebrain-lesion-induced amnesia and cholinergic neuronal deficit. ( Fuji, K; Kameyama, T; Nabeshima, T; Nishimura, H; Ogawa, S; Sasaki, Y, 1991)
"One week after kainate-induced seizure CaSR was found in the injured CA3 region of the hippocampus and very interestingly it was found up-regulated in the neurons of CA1-CA2 and dentate gyrus."1.35Identification of calcium sensing receptor (CaSR) mRNA-expressing cells in normal and injured rat brain. ( Barresi, V; Belluardo, N; Condorelli, DF; Mudò, G; Trovato-Salinaro, A, 2009)
" Dose-response studies indicated that G-CSF could increase grey matter lesions even at lower dosages (22 and 66 microg/kg)."1.33Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice. ( Górna, A; Gressens, P; Griesmaier, E; Keller, M; Sarkozy, G; Schwendimann, L; Simbruner, G; Tinhofer, I; Urbanek, M, 2006)
"Perinatal brain injuries often result in irreversible learning disabilities, which manifest in early childhood."1.33Treatment-induced prevention of learning deficits in newborn mice with brain lesions. ( Bouslama, M; Chauvière, L; Fontaine, RH; Gallego, J; Gressens, P; Matrot, B, 2006)

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.75)18.7374
1990's8 (14.04)18.2507
2000's31 (54.39)29.6817
2010's16 (28.07)24.3611
2020's1 (1.75)2.80

Authors

AuthorsStudies
Baranoglu Kilinc, Y1
Dilek, M1
Kilinc, E1
Torun, IE1
Saylan, A1
Erdogan Duzcu, S1
Grayson, DS1
Bliss-Moreau, E1
Bennett, J1
Lavenex, P1
Amaral, DG1
Descloux, C1
Ginet, V1
Rummel, C1
Truttmann, AC1
Puyal, J1
Posod, A3
Wechselberger, K3
Schmid, A1
Huber, E1
Urbanek, M4
Kiechl-Kohlendorfer, U3
Griesmaier, E4
Swerdlow, NR2
Powell, SB2
Breier, MR2
Hines, SR1
Light, GA2
Nobs, L1
Nestel, S1
Kulik, A1
Nitsch, C1
Atanasoski, S1
Wegleiter, K2
Hermann, M1
Stanika, RI1
Obermair, GJ1
Bataveljic, D1
Petrovic, J1
Lazic, K1
Saponjic, J1
Andjus, P1
Swick, JC1
Alhadeff, AL1
Grill, HJ1
Urrea, P1
Lee, SM1
Roh, H1
Baird, JP1
Busse, S1
Schwarting, RK1
Neubauer, V1
Keller, M3
Doverhag, C1
Karlsson, A1
Hedtjarn, M1
Nilsson, U1
Kapeller, E1
Sarkozy, G2
Klimaschewski, L1
Humpel, C1
Hagberg, H1
Simbruner, G2
Gressens, P10
Savman, K1
El-Rawas, R1
Saadé, NE1
Thiriet, N1
Atweh, S1
Jaber, M1
Al-Amin, HA1
Mudò, G3
Trovato-Salinaro, A1
Barresi, V1
Belluardo, N2
Condorelli, DF2
Adén, U1
Favrais, G1
Plaisant, F2
Winerdal, M1
Felderhoff-Mueser, U1
Lampa, J1
Lelièvre, V2
Chen, A1
Siow, B1
Blamire, AM1
Lako, M1
Clowry, GJ1
Titomanlio, L1
Bouslama, M2
Le Verche, V1
Dalous, J1
Kaindl, AM2
Tsenkina, Y1
Lacaud, A1
Peineau, S2
El Ghouzzi, V1
Sokolowska, P1
Passemard, S1
Mok, A1
Schwendimann, L2
Gozes, I1
Shoemaker, JM1
Saint Marie, RL1
Neary, AC1
Geyer, MA1
Stevens, KE1
Degos, V1
Gouadon, E1
Chhor, V1
Loron, G1
Le Charpentier, T1
Josserand, J1
Ali, C1
Vivien, D1
Collingridge, GL1
Lombet, A1
Issa, L1
Rene, F1
Loeffler, JP1
Kavelaars, A1
Verney, C2
Mantz, J1
Ashe, PC1
Chlan-Fourney, J1
Juorio, AV1
Li, XM1
Vamecq, J1
Maurois, P1
Bac, P1
Bailly, F1
Bernier, JL1
Stables, JP1
Husson, I2
Dommergues, MA1
Rangel, A1
Gonzalez, LE1
Villarroel, V1
Hernandez, L1
Jakobsson, J2
Georgievska, B1
Ericson, C1
Lundberg, C2
Mesplès, B1
Medja, F1
Leroux, P2
Kosofsky, B1
Ishida, K1
Shimizu, H1
Hida, H1
Urakawa, S1
Ida, K1
Nishino, H1
Chauveau, F1
Célérier, A1
Ognard, R1
Pierard, C1
Béracochéa, D1
Satorra-Marín, N1
Núria, SM1
Homs-Ormo, S1
Sandra, HO1
Arévalo-García, R1
Rosa, AG1
Morgado-Bernal, I1
Ignacio, MB1
Coll-Andreu, M1
Margalida, CA1
Ward-Robinson, J1
Coutureau, E1
Honey, RC2
Killcross, AS1
Ainge, JA1
Heron-Maxwell, C1
Theofilas, P1
Wright, P1
de Hoz, L1
Wood, ER1
Risterucci, C1
Coccurello, R1
Banasr, M1
Stutzmann, JM1
Amalric, M1
Nieoullon, A1
Bucci, DJ1
Chess, AC1
Górna, A1
Tinhofer, I1
Rosenqvist, N1
Mårild, K1
V Agoston, D1
Chauvière, L1
Fontaine, RH1
Matrot, B1
Gallego, J1
Hennebert, O1
Legros, H1
Laudenbach, V1
Carmeliet, P1
Marret, S1
Good, MA1
Barnes, P1
Staal, V1
McGregor, A1
Whishaw, IQ1
Zeeb, F1
Erickson, C1
McDonald, RJ1
Walker, AG1
Steinmetz, JE1
Murata, Y1
Higo, N1
Oishi, T1
Yamashita, A1
Matsuda, K1
Hayashi, M1
Yamane, S1
Harich, S1
Koch, M1
Schwabe, K1
Huxlin, KR1
Williams, JM1
Price, T1
Cheng, Q1
Di Liberto, V1
Caniglia, G1
Salin, T1
Dell'Albani, P1
Corsaro, M1
Jiang, XH1
Timmusk, T1
Honkaniemi, J1
Sagar, SM1
Pyykönen, I1
Hicks, KJ1
Sharp, FR1
Horsburgh, K1
Inglis, FM1
McCulloch, J1
Liu, P1
Bilkey, DK1
Morris, R1
Frey, S1
Kasambira, T1
Petrides, M1
Eijkenboom, M1
Blokland, A1
van der Staay, FJ1
Marini, G1
Tredici, G1
Mancia, M1
Ciani, E1
Baldinotti, I1
Contestabile, A1
Gerlai, RT1
McNamara, A1
Williams, S1
Phillips, HS1
Quian Quiroga, R1
Kraskov, A1
Kreuz, T1
Grassberger, P1
McDonald, JW1
Trescher, WH1
Johnston, MV1
Nabeshima, T1
Ogawa, S1
Nishimura, H1
Fuji, K1
Kameyama, T1
Sasaki, Y1
Katz, IR1
Iacovitti, L1
Reis, DJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome[NCT02304302]Phase 2160 participants (Actual)Interventional2014-10-31Completed
Visual Restoration of Losses Caused by Cortical Damage: a New Protocol to Promote Fast Recovery[NCT05085210]92 participants (Anticipated)Interventional2022-01-25Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adaptive/Behavioral Functioning of the Participants as Assessed by Change in Score on the Scales of Independent Behavior-Revised (SIB-R)

This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these were used as dependent variables. We report here on the Broad Independence Score recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the SIB-R Score Scale in this study was -24 (this number is below 0 because -24 was the minimum value for the worst performing participant in the trial) and the maximum value of this scale is 153; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo6.88
Memantine3.23

Efficacy of the Drug Memantine as Assessed by Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall

The primary efficacy measure is focused on episodic memory. The CVLT-II short form assesses supraspan word learning ability as an index of episodic verbal long-term memory. We hypothesize that treatment with memantine will produce significant improvements in this test. The main dependent variable selected, based on prior literature was the total number of target items correct summed across learning trials 1-4. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). Scale Range: from 0 to 36; higher scores represent better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo3.3
Memantine3.49

Efficacy of the Drug Memantine as Assessed by Change in Score on the Paired Associates Learning (PAL) From the Cambridge Neuropsychological Test Automated Battery (CANTAB)

This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the PAL Memory Score Scale is 0 and the maximum value is 21; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo1
Memantine0.67

Efficacy of the Drug Memantine as Assessed by Change in Score on the Pattern Recognition Memory (PRM; Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)

This is a measure of non-verbal memory. Total number correct across the two series of items presented was used as the dependent variable. We used the PRM total scale in this study, which represents the sum of the PRM correct scores (ranging from 0 to 24) and the PRM delayed scores (ranging from 0 to 24). Therefore, the range of the PRM total scale is from 0 to 48; higher values mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo0.45
Memantine-0.05

Efficacy of the Drug Memantine as Assessed by Change in Score on the Recall of Digits Forward (From the Differential Ability Scales; DAS-II)

This is a measure of rote short-term verbal memory. Total number of items correct were used as the dependent variable. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 38; higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo0.03
Memantine-0.01

Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Span (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)

This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. The main dependent variables selected for this test was the span length, which is the longest sequence of numbers recalled accurately. The minimum value of the Spatial Span Length Score Scale is 0 and the maximum value is 9; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo0.13
Memantine0.03

Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Working Memory (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)

"The test requires participants to search under a series of colored boxes to locate a blue token hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. The main dependent variable was the total number of errors (between errors), which indexes the number of times a participant went back to a box where a token had already been found, lower scores mean better performance. The minimum value of the Spatial Working Memory scale is 0 and the maximum value is 137 (which was computed as the equivalent to -4 standard deviations from the mean of this measure); higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo-0.09
Memantine-1.4

Efficacy of the Drug Memantine as Assessed by Change in Score on the The Go - No Go Task

"This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior go or no-go cues in a classical conditioning paradigm. The main dependent variables selected was speed of response of execution to Go targets. The minimum value of the speed of response of execution to Go targets is 280 milliseconds (ms) and the maximum value is 1000 ms; higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionms (Mean)
Placebo-2.52
Memantine0.22

Intellectual Functioning of the Participants as Assessed by Change in Score on the Matrices Subtest of the Differential Ability Scales-II (DAS-II)

This test provides a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants. The minimum value of the DAS-II Rasch Score Scale is 0 and the maximum value is 153; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo0.75
Memantine2.66

Linguistic Functioning of the Participants as Assessed by Change in Score on the Peabody Picture Vocabulary Test-IV (PPVT-IV)

This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 192, higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo4.46
Memantine5.63

Linguistic Functioning of the Participants as Assessed by Change in Score on the Test for Reception of Grammar 2nd Edition (TROG-II)

This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the scores is 0 and the maximum value is 40; with higher scores considered to be a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionscore on a scale (Mean)
Placebo0.49
Memantine0.89

Safety and Tolerability of the Drug Memantine as Assessed by Change in QTc Interval

Incidence of adverse events was monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, the Screen for Childhood Anxiety Related Emotional Disorders (SCARED). Here, we report the analysis of the effect of memantine treatment on QTc intervals because of its clinical importance for this analysis for potential drug toxicity. QTc intervals ≥ 450 ms are generally considered long, and drug-induced QTc interval prolongations ≥ 60 ms are generally considered clinically relevant. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment

Interventionms (Mean)
Placebo-1.30
Memantine-0.11

Other Studies

57 other studies available for ibotenic acid and Brain Injuries

ArticleYear
Capsaicin attenuates excitotoxic-induced neonatal brain injury and brain mast cell-mediated neuroinflammation in newborn rats.
    Chemico-biological interactions, 2023, May-01, Volume: 376

    Topics: Animals; Animals, Newborn; Brain Injuries; Capsaicin; Cytokines; Encephalitis; Gray Matter; Ibotenic

2023
Neural Reorganization Due to Neonatal Amygdala Lesions in the Rhesus Monkey: Changes in Morphology and Network Structure.
    Cerebral cortex (New York, N.Y. : 1991), 2017, 06-01, Volume: 27, Issue:6

    Topics: Amygdala; Animals; Animals, Newborn; Brain Injuries; Connectome; Diffusion Magnetic Resonance Imagin

2017
Enhanced autophagy contributes to excitotoxic lesions in a rat model of preterm brain injury.
    Cell death & disease, 2018, 08-28, Volume: 9, Issue:9

    Topics: Animals; Animals, Newborn; Autophagy; Brain; Brain Injuries; Disease Models, Animal; Female; Iboteni

2018
Excitotoxicity Alters Endogenous Secretoneurin Plasma Levels, but Supplementation with Secretoneurin Does Not Protect Against Excitotoxic Neonatal Brain Injury.
    Neuroscience, 2019, 07-01, Volume: 410

    Topics: Animals; Animals, Newborn; Biomarkers; Brain Injuries; Ibotenic Acid; Mice; Neuropeptides; Neuroprot

2019
Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats.
    Neuropharmacology, 2013, Volume: 75

    Topics: Acoustic Stimulation; Age Factors; Animals; Animals, Newborn; Brain Injuries; Cell Adhesion Molecule

2013
Cyclin D1 is required for proliferation of Olig2-expressing progenitor cells in the injured cerebral cortex.
    Glia, 2013, Volume: 61, Issue:9

    Topics: Adult Stem Cells; Analysis of Variance; Animals; Basic Helix-Loop-Helix Transcription Factors; Brain

2013
The sigma-1 receptor agonist 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) protects against newborn excitotoxic brain injury by stabilizing the mitochondrial membrane potential in vitro and inhibiting microglial activation in vivo.
    Experimental neurology, 2014, Volume: 261

    Topics: Animals; Animals, Newborn; Apoptosis; Apoptosis Inducing Factor; Brain Injuries; Caspase 3; Disease

2014
Glial response in the rat models of functionally distinct cholinergic neuronal denervations.
    Journal of neuroscience research, 2015, Volume: 93, Issue:2

    Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cholinergic Neurons; Denervation; Dise

2015
Parabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:8

    Topics: Analysis of Variance; Animals; Antimanic Agents; Appetitive Behavior; Brain Injuries; Eating; Excita

2015
Procedural Performance Benefits after Excitotoxic Hippocampal Lesions in the Rat Sequential Reaction Time Task.
    Neurotoxicity research, 2016, Volume: 29, Issue:1

    Topics: Analysis of Variance; Animals; Brain Injuries; Conditioning, Operant; Disease Models, Animal; Excita

2016
Delayed application of the haematopoietic growth factors G-CSF/SCF and FL reduces neonatal excitotoxic brain injury.
    Brain research, 2016, Mar-01, Volume: 1634

    Topics: Animals; Animals, Newborn; Apoptosis; Brain Injuries; Cerebral Cortex; Excitatory Amino Acid Agonist

2016
Pharmacological and genetic inhibition of NADPH oxidase does not reduce brain damage in different models of perinatal brain injury in newborn mice.
    Neurobiology of disease, 2008, Volume: 31, Issue:1

    Topics: Animals; Animals, Newborn; Apoptosis; Brain Injuries; Excitatory Amino Acid Agonists; Female; Gene E

2008
Developmental changes in the mRNA expression of neuropeptides and dopamine and glutamate receptors in neonates and adult rats after ventral hippocampal lesion.
    Schizophrenia research, 2009, Volume: 113, Issue:2-3

    Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain Injuries; Dynorphins; Enkephalin

2009
Identification of calcium sensing receptor (CaSR) mRNA-expressing cells in normal and injured rat brain.
    Brain research, 2009, Nov-17, Volume: 1298

    Topics: Animals; Brain; Brain Injuries; Cell Count; Ibotenic Acid; Immunohistochemistry; In Situ Hybridizati

2009
Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFalpha pathway and protection by etanercept.
    Brain, behavior, and immunity, 2010, Volume: 24, Issue:5

    Topics: Animals; Blotting, Western; Brain; Brain Injuries; Calcium-Binding Proteins; Caspase 3; Enzyme-Linke

2010
Transplantation of magnetically labeled mesenchymal stem cells in a model of perinatal brain injury.
    Stem cell research, 2010, Volume: 5, Issue:3

    Topics: Animals; Animals, Newborn; Brain Injuries; Cell Differentiation; Cell Proliferation; Disease Models,

2010
Implanted neurosphere-derived precursors promote recovery after neonatal excitotoxic brain injury.
    Stem cells and development, 2011, Volume: 20, Issue:5

    Topics: Animals; Animals, Newborn; Brain Injuries; Brain Tissue Transplantation; Cell Differentiation; Cell

2011
Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.
    Neuroscience, 2011, Jan-26, Volume: 173

    Topics: Animals; Animals, Newborn; Apoptosis; Blotting, Western; Brain Injuries; Cerebral Palsy; Disease Mod

2011
Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats.
    Developmental neuroscience, 2012, Volume: 34, Issue:2-3

    Topics: Acoustic Stimulation; Animals; Animals, Newborn; Brain Injuries; Hippocampus; Ibotenic Acid; Male; R

2012
Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain.
    Annals of neurology, 2012, Volume: 72, Issue:4

    Topics: Animals; Brain; Brain Injuries; Calcium; Cell Death; Cell Survival; Cells, Cultured; Culture Media,

2012
Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus.
    Brain research, 2002, Nov-22, Volume: 956, Issue:1

    Topics: Animals; Animals, Newborn; Brain Injuries; Brain-Derived Neurotrophic Factor; Excitatory Amino Acid

2002
Potent mammalian cerebroprotection and neuronal cell death inhibition are afforded by a synthetic antioxidant analogue of marine invertebrate cell protectant ovothiols.
    The European journal of neuroscience, 2003, Volume: 18, Issue:5

    Topics: Animals; Animals, Newborn; Behavior, Animal; Benzimidazoles; Brain; Brain Injuries; Cell Death; Dise

2003
Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection.
    Neuroscience, 2003, Volume: 121, Issue:3

    Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Antirheumatic Agents; Brain; Brain Injuries; Cell

2003
Anxiolysis followed by anxiogenesis relates to coping and corticosterone after medial prefrontal cortical damage in rats.
    Brain research, 2003, Nov-28, Volume: 992, Issue:1

    Topics: Animals; Anxiety; Behavior, Animal; Brain Injuries; Corticosterone; Frontal Lobe; Ibotenic Acid; Inj

2003
Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector.
    The European journal of neuroscience, 2004, Volume: 19, Issue:3

    Topics: Animals; Brain Injuries; Cell Count; Enzyme-Linked Immunosorbent Assay; Excitatory Amino Acid Agonis

2004
Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties.
    Neuroscience, 2004, Volume: 125, Issue:1

    Topics: Animals; Animals, Newborn; Apoptosis; Brain; Brain Injuries; Dizocilpine Maleate; Dopamine Uptake In

2004
Argyrophilic dark neurons represent various states of neuronal damage in brain insults: some come to die and others survive.
    Neuroscience, 2004, Volume: 125, Issue:3

    Topics: Animals; Brain; Brain Diseases; Brain Injuries; Caspase 3; Caspases; Cell Death; Cytoskeleton; Dendr

2004
Effects of ibotenic acid lesions of the mediodorsal thalamus on memory: relationship with emotional processes in mice.
    Behavioural brain research, 2005, Jan-30, Volume: 156, Issue:2

    Topics: Animals; Behavior, Animal; Brain Injuries; Emotions; Ibotenic Acid; Male; Maze Learning; Mediodorsal

2005
Effects of pre-training pedunculopontine tegmental nucleus lesions on delayed matching- and non-matching-to-position in a T-maze in rats.
    Behavioural brain research, 2005, May-07, Volume: 160, Issue:1

    Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Brain Injuries; Choice Behavior; Excitator

2005
Excitotoxic lesions of the entorhinal cortex leave gustatory within-event learning intact.
    Behavioral neuroscience, 2005, Volume: 119, Issue:4

    Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Injuries; Discrimination Learning; Entorhinal

2005
The role of the hippocampus in object recognition in rats: examination of the influence of task parameters and lesion size.
    Behavioural brain research, 2006, Feb-15, Volume: 167, Issue:1

    Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Injuries; Choice Behavior; Exploratory Behavi

2006
The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions.
    Neuroscience, 2006, Volume: 137, Issue:1

    Topics: Animals; Brain Injuries; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Ibotenic

2006
Specific changes in conditioned responding following neurotoxic damage to the posterior parietal cortex.
    Behavioral neuroscience, 2005, Volume: 119, Issue:6

    Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Injuries; Conditioning, Classical; Ibotenic A

2005
Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice.
    Pediatric research, 2006, Volume: 59, Issue:4 Pt 1

    Topics: Animals; Animals, Newborn; Apoptosis; Brain; Brain Injuries; Dose-Response Relationship, Drug; Excit

2006
Evidence for disease-regulated transgene expression in the brain with use of lentiviral vectors.
    Journal of neuroscience research, 2006, Volume: 84, Issue:1

    Topics: Animals; Animals, Genetically Modified; beta-Galactosidase; Brain; Brain Injuries; Functional Latera

2006
Treatment-induced prevention of learning deficits in newborn mice with brain lesions.
    Neuroscience, 2006, Aug-25, Volume: 141, Issue:2

    Topics: Animals; Animals, Newborn; Behavior, Animal; Brain Injuries; Conditioning, Classical; Discrimination

2006
Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs.
    Neuroscience, 2007, May-11, Volume: 146, Issue:2

    Topics: Analysis of Variance; Animals; Animals, Newborn; Brain Injuries; Cysts; Disease Models, Animal; Dose

2007
Context- but not familiarity-dependent forms of object recognition are impaired following excitotoxic hippocampal lesions in rats.
    Behavioral neuroscience, 2007, Volume: 121, Issue:1

    Topics: Animals; Brain Injuries; Hippocampus; Ibotenic Acid; Male; Memory Disorders; Mental Recall; Neuropsy

2007
Neurotoxic lesions of the caudate-putamen on a reaching for food task in the rat: acute sensorimotor neglect and chronic qualitative motor impairment follow lateral lesions and improved success follows medial lesions.
    Neuroscience, 2007, Apr-25, Volume: 146, Issue:1

    Topics: Animals; Behavior, Animal; Brain Injuries; Cell Death; Conditioning, Operant; Feeding Behavior; Func

2007
Hippocampal lesions in rats differentially affect long- and short-trace eyeblink conditioning.
    Physiology & behavior, 2008, Feb-27, Volume: 93, Issue:3

    Topics: Analysis of Variance; Animals; Behavior, Animal; Blinking; Brain Injuries; Conditioning, Eyelid; Exc

2008
Effects of motor training on the recovery of manual dexterity after primary motor cortex lesion in macaque monkeys.
    Journal of neurophysiology, 2008, Volume: 99, Issue:2

    Topics: Animals; Brain Injuries; Brain Mapping; Electric Stimulation; Fingers; Functional Laterality; Hand S

2008
Effects of repeated dizocilpine treatment on adult rat behavior after neonatal lesions of the entorhinal cortex.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Apr-01, Volume: 32, Issue:3

    Topics: Acoustic Stimulation; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Brain Injur

2008
A neurochemical signature of visual recovery after extrastriate cortical damage in the adult cat.
    The Journal of comparative neurology, 2008, May-01, Volume: 508, Issue:1

    Topics: Amino Acids; Animals; Behavior, Animal; Brain Chemistry; Brain Injuries; Brain Mapping; Cats; Female

2008
Time-course of GDNF and its receptor expression after brain injury in the rat.
    Neuroscience letters, 2008, Jul-04, Volume: 439, Issue:1

    Topics: Animals; Autoradiography; Brain Injuries; Gene Expression Regulation; Glial Cell Line-Derived Neurot

2008
Neurotoxic injury in rat hippocampus differentially affects multiple trkB and trkC transcripts.
    Neuroscience letters, 1995, Aug-18, Volume: 196, Issue:1-2

    Topics: Animals; Autoradiography; Blotting, Northern; Brain Injuries; Hippocampus; Ibotenic Acid; In Situ Hy

1995
Focal brain injury induces multiple immediate early genes encoding zinc finger transcription factors.
    Brain research. Molecular brain research, 1995, Volume: 28, Issue:1

    Topics: Animals; Brain Injuries; Cerebral Cortex; Gene Expression; Hippocampus; Ibotenic Acid; In Situ Hybri

1995
Focal increases in [3H]forskolin and [3H]phorbol 12,13-dibutyrate binding in the rat brain following lesions of the medial septum.
    Neuroscience letters, 1993, Mar-19, Volume: 151, Issue:2

    Topics: Adenylyl Cyclases; Animals; Autoradiography; Brain Chemistry; Brain Injuries; Colforsin; Hippocampus

1993
Excitotoxic lesions centered on perirhinal cortex produce delay-dependent deficits in a test of spatial memory.
    Behavioral neuroscience, 1998, Volume: 112, Issue:3

    Topics: Analysis of Variance; Animals; Brain Injuries; Cues; Electricity; Hippocampus; Ibotenic Acid; Limbic

1998
Ibotenic acid lesions of the basolateral, but not the central, amygdala interfere with conditioned taste aversion: evidence from a combined behavioral and anatomical tract-tracing investigation.
    Behavioral neuroscience, 1999, Volume: 113, Issue:2

    Topics: Amygdala; Animals; Avoidance Learning; Brain Injuries; Brain Mapping; Conditioning, Classical; Ibote

1999
Modelling cognitive dysfunctions with bilateral injections of ibotenic acid into the rat entorhinal cortex.
    Neuroscience, 2000, Volume: 101, Issue:1

    Topics: Brain Injuries; Cognition Disorders; Disease Models, Animal; Entorhinal Cortex; Functional Lateralit

2000
Abolition of the neocortically monitored theta rhythm after ibotenic acid lesion of the parafascicular nucleus in behaving rats.
    Sleep research online : SRO, 1998, Volume: 1, Issue:4

    Topics: Animals; Brain Injuries; Ibotenic Acid; Intralaminar Thalamic Nuclei; Rats; Rats, Sprague-Dawley; Th

1998
Sustained, long-lasting inhibition of nitric oxide synthase aggravates the neural damage in some models of excitotoxic brain injury.
    Brain research bulletin, 2001, Sep-01, Volume: 56, Issue:1

    Topics: Animals; Basal Nucleus of Meynert; Brain; Brain Injuries; Calcium Channel Blockers; Choline O-Acetyl

2001
Hippocampal dysfunction and behavioral deficit in the water maze in mice: an unresolved issue?
    Brain research bulletin, 2002, Jan-01, Volume: 57, Issue:1

    Topics: Animals; Behavior, Animal; Brain Injuries; Disease Models, Animal; Excitatory Amino Acid Agonists; F

2002
Performance of different synchronization measures in real data: a case study on electroencephalographic signals.
    Physical review. E, Statistical, nonlinear, and soft matter physics, 2002, Volume: 65, Issue:4 Pt 1

    Topics: Animals; Brain Injuries; Cortical Synchronization; Disease Models, Animal; Epilepsy, Absence; Humans

2002
Susceptibility of brain to AMPA induced excitotoxicity transiently peaks during early postnatal development.
    Brain research, 1992, Jun-26, Volume: 583, Issue:1-2

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Aci

1992
Staurosporine, a protein kinase inhibitor, attenuates basal forebrain-lesion-induced amnesia and cholinergic neuronal deficit.
    Neuroscience letters, 1991, Jan-14, Volume: 122, Issue:1

    Topics: Alkaloids; Amnesia; Animals; Autonomic Nervous System Diseases; Brain; Brain Injuries; Cerebral Cort

1991
Cells proliferating in vitro to local brain injury are primarily of hematic origin and differ from those associated with anterograde degeneration.
    Annals of the New York Academy of Sciences, 1988, Volume: 540

    Topics: Animals; Antibodies, Monoclonal; Antigens, Surface; Brain Injuries; Caudate Nucleus; Cell Division;

1988